Oncology Analysis
🌏 NMPAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 14 articles
ASCO26: Revolution's Daraxonrasib Phase III Data Reshapes Pancreatic Cancer Odds
Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide
SAKIGAKE Designation Japan: Bispecific Antibodies for Leukemia Status 2026
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
NMPA Approval ADCs Lung Cancer: Trends & Clinical Insights 2025
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
Chinese-Developed ADCs Integration: Clinical Impact & Regulatory Advances in APAC
APAC KRAS Inhibitors: Elisrasib’s Promise in Advanced NSCLC
Radioligand Therapies for Prostate Cancer: Market Access and Clinical Insights in APAC
NMPA Priority Review Pathway: What You Need to Know About Innovative Drug Approvals